PB1120: A long-acting VIP
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino acid neuropeptide with multiple pleiotropic effects, including vasodilatory, inotropic/lusitropic and antifibrotic effects, which are mediated by two G-protein coupled receptors: VPAC1 and VPAC2. VPAC receptors and nerve fibers containing VIP are widely distributed throughout the pulmonary vasculature, myocardial tissue, and systemic and coronary arteries.
To date, the inherently poor in vivo stability and bioavailability of the native VIP peptide has precluded its use as a therapeutic. PhaseBio’s PB1120, a genetic fusion of VIP to our ELP biopolymer, overcomes these limitations and demonstrates prolonged circulatory drug exposure and potent activity. PB1120 was designed to have similar potency for activation of the VPAC1 and VPAC2 receptors.
PB1120 is being evaluated in pre-clinical studies for potential use in indications where VPAC1 agonist activity may be beneficial (e.g., cystic fibrosis).